Autophagy Modulators for Diamond Blackfan Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for ribosomal disorders and ribosomopathies, such as Diamond Blackfan Anemia, are inadequate, necessitating the development of effective screening methods and targeted therapies.
Innovation Solution
The use of autophagy modulators, specifically compounds like SMER28, to treat ribosomal disorders by promoting erythroid differentiation, increasing hemoglobin levels, and reducing p21 and apoptosis in hematopoietic cells, along with methods for screening agents that enhance hematopoietic cell differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment options are used for ribosomal disorders, then patients receive standard care, but treatment effectiveness is inadequate
Solution Approach 1:
The patent changes the therapeutic parameter by targeting autophagy modulation rather than conventional ribosomal protein synthesis inhibitors. The compound SMER28 modulates autophagy to specifically enhance erythroid differentiation and reduce p21 expression, achieving superior treatment effectiveness compared to standard care while addressing the inadequate therapeutic outcomes of current treatments
Solution Approach 2:
The patent introduces autophagy as an intermediary mechanism between ribosomal disorder and therapeutic intervention. By modulating autophagy flux through SMER28, the compound creates a beneficial intermediate effect that promotes erythroid differentiation and reduces apoptosis, thereby improving treatment effectiveness without directly targeting the ribosomal defect
2Quantity of substance
If autophagy modulators are administered to increase erythroid differentiation, then hemoglobin levels increase, but the mechanism is complex
Solution Approach 1:
The patent extracts and isolates the critical autophagy modulation function from the complex cellular processes. By using SMER28 to specifically modulate autophagy flux, the compound separates the essential function of enhancing erythroid differentiation from the complexity of ribosomal protein synthesis, thereby increasing hemoglobin levels through a targeted mechanism
Solution Approach 2:
The patent segments the cellular process into distinct functional components: autophagy modulation by SMER28, erythroid differentiation enhancement, and hemoglobin production. This segmentation allows the compound to act specifically on the autophagy pathway to achieve hemoglobin increase without requiring complex direct manipulation of ribosomal proteins
3Adaptability or versatility
If screening methods are developed to find treatments, then new therapies can be discovered, but the screening process is time-consuming
Solution Approach 1:
The patent performs preliminary action by establishing a validated screening method using zebrafish embryos that can predict therapeutic effectiveness before human clinical trials. The screening assay measures erythroid differentiation and hemoglobin levels in embryos treated with candidate compounds, allowing rapid identification of promising therapies without time-consuming extensive testing
Solution Approach 2:
The patent uses zebrafish embryos as a copy model of human ribosomal disorders. The screening method tests compounds on zebrafish embryos with ribosomal defects, and the results copy-predict human therapeutic response. This animal model copying allows rapid screening of many compounds simultaneously, reducing the time needed for therapy discovery compared to direct human testing
Data Source
AI summary
The present invention relates generally to methods for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of a small-molecule autophagy modulator for treatment of ribosomal disorders and ribosomopathy. The invention also relates to small molecule drug discovery and methods of screening compositions to determine their effectiveness for treatment of ribosomal disorders and ribosomopathies.